Sponsored By

FutureCeuticals, BioBoron Advance FruiteX-B® Research

August 9, 2011

2 Min Read
FutureCeuticals, BioBoron Advance FruiteX-B® Research

MOMENCE, Ill.FutureCeuticals Inc. partnered with BioBoron Research Institute and its director, Ion Romulus Scorei, Ph.D, with the goal to advance the scientific study and global commercialization of FruiteX-B® Calcium Fructoborate, a patented, nature-identical plant mineral complex.

As part of the cooperative research, Scorei and his team will contribute to the chemical and biological differentiation of calcium fructoborate from other boron-based compounds and borate complexes.

Scorei, professor of Biochemistry at the University of Craiova, has authored nearly a dozen published studies on calcium fructoborate's chemical and biological properties and on new potential health benefits, including, most recently, its ability to modulate inflammatory and lipid blood markers in individuals exhibiting symptoms of primary osteoarthritis.   

He is the recipient of numerous accolades for his work on calcium fructoborate, including gold medal honors from "Inventika International Fair," "International Salon of Innovation, Techniques and New Products and "International Salon of Inventions and Innovations." In 2009, he founded the BioBoron Research Institute. He also sits on the editorial board of the journal Biochemistry and Analytical Biochemistry: Current Research.

The BioBoron Research Institute, established in 2009 on a grant from the European Commission's Sectoral Operational Program for Increasing Economic Competitiveness, is equipped with GMP (good manufacturing practice) laboratories for physico-chemical and biochemical research including spectroscopy, chromatography, molecular biology and cellular culture analyses.   

"Dr. Scorei's expertise and his body of impressive existing and ongoing research into calcium fructoborate will greatly support current business initiatives as well as our planned aggressive push into Europe and other foreign markets," said John M. Hunter, general manager at FutureCeuticals, said. The organization is wrapping up its own pilot clinical study on the effect of FruiteX-B® on participant-reported joint discomfort and diminished flexibility and inflammatory blood markers associated with osteoarthritis.

FruiteX-B® Calcium Fructoborate is manufactured under U.S. Patent #5,962,049 and issued and pending foreign patents and is available exclusively from VDF FutureCeuticals Inc. A 2002 study showed it may play a positive role in hormone regulation.

Subscribe and receive the latest insights on the health and nutrition industry.
Join 37,000+ members. Yes, it's completely free.

You May Also Like